Skip to content

Does a Magnetic Resonance-Only Pathway Impact Dosimetric and Acute Clinical Outcomes in Prostate Stereotactic Ablative Body Radiotherapy?

Oct 2026 · Clinics in oncology · pp. 104356 · 0 citations
Medicine

Abstract

Aims

This study aimed to compare prostate target and organs at risk (OAR) volumes, doses, and acute toxicity scores for patients treated with prostate stereotactic ablative body radiotherapy (SABR) using magnetic resonance (MR)-only or MR registered with computed tomography (MR-CT) pathways.

Materials And Methods

A total of 486 patients prescribed 36.25 Gy in five fractions were included. Patients were treated using a. MR-CT (January-October 2024, n = 262) or MR-only (October 2024-August 2025, n = 222) pathway. Unfavourable risk patients (36% MR-only, 37% MR-CT) received additional hormone therapy. Sixty-five percent of MR-only patients and 76% of MR-CT patients attended an acute toxicity assessment two weeks post treatment using Common Toxicity Criteria. Prostate, bladder, penile bulb, and rectum volumes and dose constraints were compared between the two pathways using the Mann-Whitney U-test. The proportion of patients reporting acute toxicity of grade ≥1, ≥2, and ≥3 were compared.

Results

Median MR-only prostate volumes were 38-9+10cm3 value to third quartile, -value to first quartile, compared to MR-CT volumes of 40-10+11cm3, a 4% reduction (P = .07). For unfavourable risk patients only, the reduction was 10%, 30-7+7 cm3 (MR-only) and 33-7+7 cm3 (MR-CT, P = .04). For both favourable and unfavourable risk patients, the penile bulb mean dose was 52% lower, 2.2 Gy (MR-only) compared to 4.6 Gy (MR-CT, P < .001). There was a reduction of -20.3% (95% confidence interval: -37.4%, -3.2%) in acute grade ≥1 and -21.7% (-39.4%, -3.7%) in grade ≥2 sexual toxicities in the MR-only cohort, although the sexual toxicity response rates were low.

Conclusion

MR-only prostate SABR significantly reduced penile bulb doses and may have reduced target volumes and acute sexual toxicity while enabling improved patient experience and departmental efficiency. These findings need to be validated in larger patient cohorts with longer-term follow-up.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.